Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Daher T, Tur MK, Brobeil A, Etschmann B, Witte B, Engenhart-Cabillic R, Krombach G, Blau W, Grimminger F, Seeger W, Klussmann JP, Bräuninger A, Gattenlöhner S.

Head Neck. 2018 Jun;40(6):1109-1119. doi: 10.1002/hed.25041. Epub 2018 Mar 9.

PMID:
29522268
2.

Targeted Next-Generation Sequencing Is a Sensitive Tool for Differential Diagnosis of Myelodysplastic Syndromes in Bone Marrow Trephines.

Bräuninger A, Blau W, Kunze K, Desch AK, Brobeil A, Tur MK, Etschmann B, Günther U, Körholz D, Schliesser G, Käbisch A, Kiehl M, Rummel M, Gattenlöhner S.

J Mol Diagn. 2018 May;20(3):344-354. doi: 10.1016/j.jmoldx.2018.01.006. Epub 2018 Feb 19.

PMID:
29471115
3.

Antibody Selection on FFPE Tissue Slides.

Ten Haaf A, Gattenlöhner S, Tur MK.

Methods Mol Biol. 2018;1701:381-391. doi: 10.1007/978-1-4939-7447-4_21.

PMID:
29116517
4.

Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins.

Tur MK, Daramola AK, Gattenlöhner S, Herling M, Chetty S, Barth S.

Biomedicines. 2017 Oct 4;5(4). pii: E59. doi: 10.3390/biomedicines5040059. Review.

5.

Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.

Kessler C, Pardo A, Tur MK, Gattenlöhner S, Fischer R, Kolberg K, Barth S.

J Cancer Res Clin Oncol. 2017 Oct;143(10):2025-2038. doi: 10.1007/s00432-017-2472-9. Epub 2017 Jun 30.

PMID:
28667390
6.

Development of a monoclonal sandwich ELISA for direct detection of bluetongue virus 8 in infected animals.

Ten Haaf A, Kohl J, Pscherer S, Hamann HP, Eskens HU, Bastian M, Gattenlöhner S, Tur MK.

J Virol Methods. 2017 May;243:172-176. doi: 10.1016/j.jviromet.2017.02.003. Epub 2017 Feb 11.

PMID:
28193493
7.

A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells.

Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, Herling CD, Tur MK, Hallek M, Pfitzer G, Barth S, Herling M.

Mol Cancer Ther. 2016 May;15(5):971-84. doi: 10.1158/1535-7163.MCT-15-0685. Epub 2016 Jan 29.

8.

Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies.

Ten Haaf A, Pscherer S, Fries K, Barth S, Gattenlöhner S, Tur MK.

Immunol Lett. 2015 Aug;166(2):65-78. doi: 10.1016/j.imlet.2015.05.013. Epub 2015 Jun 2.

PMID:
26045318
9.

Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein.

Brehm H, Hristodorov D, Pardo A, Mladenov R, Niesen J, Fischer R, Tur MK, Barth S.

Cancer Lett. 2015 Sep 1;365(2):149-55. doi: 10.1016/j.canlet.2015.04.004. Epub 2015 Apr 14.

PMID:
25888452
10.

Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.

Fitting J, Blume T, Ten Haaf A, Blau W, Gattenlöhner S, Tur MK, Barth S.

MAbs. 2015;7(2):390-402. doi: 10.1080/19420862.2015.1007818.

11.

In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.

Niesen J, Brehm H, Stein C, Berges N, Pardo A, Fischer R, Ten Haaf A, Gattenlöhner S, Tur MK, Barth S.

J Cancer Res Clin Oncol. 2015 Jun;141(6):1049-61. doi: 10.1007/s00432-014-1884-z. Epub 2014 Nov 30.

PMID:
25433506
12.

Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.

Kunze K, Gamerdinger U, Leßig-Owlanj J, Sorokina M, Brobeil A, Tur MK, Blau W, Burchardt A, Käbisch A, Schliesser G, Kiehl M, Rosenwald A, Rummel M, Grimminger F, Hain T, Chakraborty T, Bräuninger A, Gattenlöhner S.

Pathol Res Pract. 2014 Jun;210(6):369-76. doi: 10.1016/j.prp.2014.02.006. Epub 2014 Feb 23.

PMID:
24674452
13.

CD30 as a therapeutic target for lymphoma.

Schirrmann T, Steinwand M, Wezler X, Ten Haaf A, Tur MK, Barth S.

BioDrugs. 2014 Apr;28(2):181-209. doi: 10.1007/s40259-013-0068-8. Review.

PMID:
24043362
14.

An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing αvβ3 integrin.

Hussain AF, Tur MK, Barth S.

Nucleic Acid Ther. 2013 Jun;23(3):203-12. doi: 10.1089/nat.2012.0408. Epub 2013 Apr 1.

PMID:
23544955
15.

The 140-kD isoform of CD56 (NCAM1) directs the molecular pathogenesis of ischemic cardiomyopathy.

Tur MK, Etschmann B, Benz A, Leich E, Waller C, Schuh K, Rosenwald A, Ertl G, Kienitz A, Haaf AT, Bräuninger A, Gattenlöhner S.

Am J Pathol. 2013 Apr;182(4):1205-18. doi: 10.1016/j.ajpath.2012.12.027. Epub 2013 Feb 8.

PMID:
23462508
16.

Short-chain fluorescent tryptophan tags for on-line detection of functional recombinant proteins.

Siepert EM, Gartz E, Tur MK, Delbrück H, Barth S, Büchs J.

BMC Biotechnol. 2012 Sep 21;12:65. doi: 10.1186/1472-6750-12-65.

17.

SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells.

Hussain AF, Kampmeier F, von Felbert V, Merk HF, Tur MK, Barth S.

Bioconjug Chem. 2011 Dec 21;22(12):2487-95. doi: 10.1021/bc200304k. Epub 2011 Nov 3.

PMID:
21995499
18.

Generation of recombinant antibody fragments that target canine dendritic cells by phage display technology.

Fitting J, Killian D, Junghanss C, Willenbrock S, Murua Escobar H, Lange S, Nolte I, Barth S, Tur MK.

Vet Comp Oncol. 2011 Sep;9(3):183-95. doi: 10.1111/j.1476-5829.2010.00246.x. Epub 2010 Sep 30.

PMID:
21848621
19.

In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.

Tur MK, Huhn M, Jost E, Thepen T, Brümmendorf TH, Barth S.

Int J Cancer. 2011 Sep 1;129(5):1277-82. doi: 10.1002/ijc.25766. Epub 2011 Feb 26.

20.

Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice.

Ribbert T, Thepen T, Tur MK, Fischer R, Huhn M, Barth S.

Br J Dermatol. 2010 Aug;163(2):279-86. doi: 10.1111/j.1365-2133.2010.09824.x. Epub 2010 Apr 26.

PMID:
20426788
21.

Fcgamma receptor 1 (CD64), a target beyond cancer.

Thepen T, Huhn M, Melmer G, Tur MK, Barth S.

Curr Pharm Des. 2009;15(23):2712-8. Review.

PMID:
19689341
22.

Improved immunotoxins with novel functional elements.

Hetzel C, Bachran C, Tur MK, Fuchs H, Stöcker M.

Curr Pharm Des. 2009;15(23):2700-11. Review.

PMID:
19689340
23.

Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy.

Tur MK, Neef I, Jäger G, Teubner A, Stöcker M, Melmer G, Barth S.

Curr Pharm Des. 2009;15(23):2693-9. Review.

PMID:
19689339
24.

Targeted restoration of down-regulated DAPK2 tumor suppressor activity induces apoptosis in Hodgkin lymphoma cells.

Tur MK, Neef I, Jost E, Galm O, Jäger G, Stöcker M, Ribbert M, Osieka R, Klinge U, Barth S.

J Immunother. 2009 Jun;32(5):431-41. doi: 10.1097/CJI.0b013e31819f1cb6.

PMID:
19609235
25.

Targeted delivery of short interfering RNAs--strategies for in vivo delivery.

Wullner U, Neef I, Tur MK, Barth S.

Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):1-8. Review.

PMID:
19149683
26.

Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.

Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S.

Curr Cancer Drug Targets. 2008 Nov;8(7):554-65.

PMID:
18991566
27.

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.

Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S.

Mol Cancer Ther. 2008 Sep;7(9):2924-32. doi: 10.1158/1535-7163.MCT-08-0554.

28.

Recombinant soluble human Fcgamma receptor I with picomolar affinity for immunoglobulin G.

Paetz A, Sack M, Thepen T, Tur MK, Bruell D, Finnern R, Fischer R, Barth S.

Biochem Biophys Res Commun. 2005 Dec 30;338(4):1811-7. Epub 2005 Nov 2.

PMID:
16289041
29.

Measurement of antibody-membrane interactions by surface plasmon resonance.

Klimka A, Tur MK, Huhn M, Bierfreund U, Terrada E, Fischer R, Finnern R, Barth S.

Int J Mol Med. 2004 Oct;14(4):765-8.

PMID:
15375615
30.

Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines.

Rothe A, Klimka A, Tur MK, Pfitzner T, Huhn M, Sasse S, Mallmann P, Engert A, Barth S.

Int J Mol Med. 2004 Oct;14(4):729-35.

PMID:
15375609
31.

Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo.

Matthey B, Borchmann P, Schnell R, Tawadros S, Lange H, Huhn M, Klimka A, Tur MK, Barth S, Engert A, Hansen HP.

Int J Cancer. 2004 Sep 10;111(4):568-74.

32.

Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.

Tur MK, Huhn M, Thepen T, Stöcker M, Krohn R, Vogel S, Jost E, Osieka R, van de Winkel JG, Fischer R, Finnern R, Barth S.

Cancer Res. 2003 Dec 1;63(23):8414-9. Erratum in: Cancer Res. 2004 May 15;;64(14):3725.

33.

Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells.

Stöcker M, Tur MK, Sasse S, Krüssmann A, Barth S, Engert A.

Protein Expr Purif. 2003 Apr;28(2):211-9.

PMID:
12699683
34.

A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells.

Tur MK, Rothe A, Huhn M, Goerres U, Klimka A, Stöcker M, Engert A, Fischer R, Finner R, Barth S.

Int J Mol Med. 2003 Apr;11(4):523-7.

PMID:
12632108
35.

Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.

Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, Barth S, Engert A.

Cancer Res. 2001 Dec 15;61(24):8737-42.

36.

An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A develops specific cytotoxic activity against neuroblastoma derived cell lines.

Tur MK, Sasse S, Stöcker M, Djabelkhir K, Huhn M, Matthey B, Gottstein C, Pfitzner T, Engert A, Barth S.

Int J Mol Med. 2001 Nov;8(5):579-84.

PMID:
11605031
37.

Selection of scFv phages on intact cells under low pH conditions leads to a significant loss of insert-free phages.

Tur MK, Huhn M, Sasse S, Engert A, Barth S.

Biotechniques. 2001 Feb;30(2):404-8, 410, 412-3.

PMID:
11233610
38.

Supplemental Content

Support Center